MA41643A - Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton - Google Patents

Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton

Info

Publication number
MA41643A
MA41643A MA041643A MA41643A MA41643A MA 41643 A MA41643 A MA 41643A MA 041643 A MA041643 A MA 041643A MA 41643 A MA41643 A MA 41643A MA 41643 A MA41643 A MA 41643A
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
kinase inhibitor
pharmaceutical formulations
inhibitor pharmaceutical
bruton tyrosine
Prior art date
Application number
MA041643A
Other languages
English (en)
Other versions
MA41643B1 (fr
Inventor
Harisha Atluri
Ching Wah Chong
Robert Kuehl
Heow Tan
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Priority claimed from PCT/US2016/020467 external-priority patent/WO2016141068A1/fr
Publication of MA41643A publication Critical patent/MA41643A/fr
Publication of MA41643B1 publication Critical patent/MA41643B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA41643A 2015-03-03 2016-03-02 Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton MA41643B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127717P 2015-03-03 2015-03-03
PCT/US2016/020467 WO2016141068A1 (fr) 2015-03-03 2016-03-02 Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton

Publications (2)

Publication Number Publication Date
MA41643A true MA41643A (fr) 2018-01-09
MA41643B1 MA41643B1 (fr) 2024-02-29

Family

ID=59254075

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41643A MA41643B1 (fr) 2015-03-03 2016-03-02 Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton

Country Status (2)

Country Link
AR (1) AR103832A1 (fr)
MA (1) MA41643B1 (fr)

Also Published As

Publication number Publication date
AR103832A1 (es) 2017-06-07
MA41643B1 (fr) 2024-02-29

Similar Documents

Publication Publication Date Title
ZA201907661B (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
IL255831A (en) Inhibitors of bruton's tyrosine kinase
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
MA50541A (fr) Formulations pharmaceutiques
IL261249A (en) Dosage preparations containing Bruton's tyrosine kinase inhibitor
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
MA46867A (fr) Formulations pharmaceutiques
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
MA42303A (fr) Formulations pharmaceutiques
SI3609886T1 (sl) Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
MA42510A (fr) Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
MA42509A (fr) Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton
MA55015A (fr) Formulations pharmaceutiques
MA42546A (fr) Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations
MA49837A (fr) Compositions pharmaceutiques
EP3337463A4 (fr) Formulations pharmaceutiques
EP3302477A4 (fr) Formulations pharmaceutiques pour la libération prolongée d'ester de dinalbuphine de sébacoyle
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine
MA54095A (fr) Formulations pharmaceutiques aqueuses
EP3319980A4 (fr) Formulations permettant d'améliorer l'efficacité des médicaments hydrophobes
EP3651800A4 (fr) Formulations pharmaceutiques hydrocompressées
EP3423041A4 (fr) Compositions pharmaceutiques
EP3528818A4 (fr) Compositions pharmaceutiques